Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

281. Rotterdam Prostate Cancer Risk Calculator: Development and Usability Testing of the Mobile Phone App Full Text available with Trip Pro

Rotterdam Prostate Cancer Risk Calculator: Development and Usability Testing of the Mobile Phone App The use of prostate cancer screening tools that take into account relevant prebiopsy information (ie, risk calculators) is recommended as a way of determining the risk of cancer and the subsequent need for a prostate biopsy. This has the potential to limit prostate cancer overdiagnosis and subsequent overtreatment. mHealth apps are gaining traction in urological practice and are used by both (...) practitioners and patients for a variety of purposes.The impetus of the study was to design, develop, and assess a smartphone app for prostate cancer screening, based on the Rotterdam Prostate Cancer Risk Calculator (RPCRC).The results of the Rotterdam arm of the European Randomized Study of Screening for Prostate Cancer (ERSPC) study were used to elaborate several algorithms that allowed the risk of prostate cancer to be estimated. A step-by-step workflow was established to ensure that depending

2017 JMIR cancer

282. Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres. Full Text available with Trip Pro

Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres. The European Randomised Study of Screening for Prostate Cancer trial has shown a 21% reduction in prostate cancer (PC) mortality with prostate-specific antigen (PSA)-based screening. Sweden used a 2-yr screening interval and showed a larger mortality reduction than Finland with a 4-yr (...) between the Finnish and Swedish centres and estimated the impact of different screening protocols.If the Swedish screening protocol had been followed in Finland, 122 additional PC cases would have been diagnosed at screening, 84% of which would have been low-risk cancers, and four leading to PC death. In contrast, if a lower PSA threshold had been applied in Finland, at least 127 additional PC would have been found, with 19 PC deaths.The small number of deaths among cases that would have been

2017 European urology focus Controlled trial quality: uncertain

283. Prostate Cancer Screening

you like to save your information to view later? Create an account and sign in to keep your Decision box results and view them later. You can also: Continue without an account and print your profile when the process is completed Prostate Cancer Screening Men between the ages of 55 and 69 with at least a 10-year life expectancy. Screening is appropriate for people who do not carry a disease that affects their life expectancy. The prostate-specific antigen (PSA) blood test is used to screen men (...) Prostate Cancer Screening Boîte à décision | Box details Back to the Decision boxes × My account Creating an account and signing in will allow you to keep your Decision box results and view them later. I do not have an account Provide some personal information and create a user account allowing to save your Decision box results and view them later. You can also: I already have an account Please enter your email address and password to access your profile and consult your decision boxes. Email

2017 Cancer Council Australia

284. Prostate cancer screening and early diagnosis

Prostate cancer screening and early diagnosis Canadian Urological Association recommendations on prostate cancer screening and early diagnosis To view this page ensure that Adobe Flash Player version 10.0.0 or greater is installed. Besides, it's possible to , or you can view flippdf Either scripts and active content are not permitted to run or Adobe Flash Player version 10.0.0 or greater is not installed. Besides, it's possible to , or you can view flippdf

2017 Canadian Urological Association

285. Magnetic resonance imaging-guided in-bore biopsy for prostate cancer

, Inc. Directory Publication. 2017 Authors' conclusions Rationale: Targeted magnetic resonance imaging (MRI)-guided biopsy techniques, such as MRI-guided in-bore (MRI-IB) biopsy, have been developed to increase identification of clinically significant prostate cancer without increasing the detection of clinically nonsignificant tumors. Technology Description: MRI-IB biopsy is a technique that uses MRI images captured in real time and processed by interventional planning software to help insert (...) provide accurate diagnostic and/or staging information for men with suspected or diagnosed prostate cancer? Does use of MRI-IB biopsy improve patient management or outcomes? Is MRI-IB biopsy safe? Have definitive patient selection criteria been established for MRI-IB-biopsy? Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Biopsy; Humans; Magnetic Resonance Imaging; Male; Prostatic Neoplasms Language Published English Country of organisation

2017 Health Technology Assessment (HTA) Database.

286. Mindfulness-Based Cognitive Therapy in Advanced Prostate Cancer: A Randomized Controlled Trial Full Text available with Trip Pro

Mindfulness-Based Cognitive Therapy in Advanced Prostate Cancer: A Randomized Controlled Trial Purpose Advanced prostate cancer (PC) is associated with substantial psychosocial morbidity. We sought to determine whether mindfulness-based cognitive therapy (MBCT) reduces distress in men with advanced PC. Methods Men with advanced PC (proven metastatic and/or castration-resistant biochemical progression) were randomly assigned to an 8-week, group-based MBCT intervention delivered by telephone (n (...) = 94) or to minimally enhanced usual care (n = 95). Primary intervention outcomes were psychological distress, cancer-specific distress, and prostate-specific antigen anxiety. Mindfulness skills were assessed as potential mediators of effect. Participants were assessed at baseline and were followed up at 3, 6, and 9 months. Main statistical analyses were conducted on the basis of intention to treat. Results Fourteen MBCT groups were conducted in the intervention arm. Facilitator adherence ratings

2017 EvidenceUpdates

287. Irreversible electroporation for treating prostate cancer

prostate surgery. 2 2 Indications and current treatments Indications and current treatments 2.1 Prostate cancer is usually diagnosed after a blood test in primary care has shown elevated prostate-specific antigen (PSA) levels. A raised PSA is not diagnostic of prostate cancer and a prostate biopsy is required to confirm the diagnosis and further tests are required to stage the extent of the disease. A NICE guideline describes recommendations for the diagnosis and management of prostate cancer. 2.2 Most (...) prostate cancers are either localised or locally advanced at diagnosis. Localised prostate cancer does not usually cause any symptoms, but some men might have some urinary problems or erectile dysfunction. Current treatments for localised disease include active surveillance, radical prostatectomy, external beam radiotherapy and brachytherapy. Hormone therapy (androgen deprivation or anti-androgens) is usually the primary treatment for metastatic prostate cancer, but is increasingly being used

2017 National Institute for Health and Clinical Excellence - Interventional Procedures

288. Detection of prostate cancer local recurrence following radical prostatectomy: assessment using a continuously acquired radial golden-angle compressed sensing acquisition Full Text available with Trip Pro

Detection of prostate cancer local recurrence following radical prostatectomy: assessment using a continuously acquired radial golden-angle compressed sensing acquisition To compare image quality and diagnostic performance for detecting local recurrence (LR) of prostate cancer after radical prostatectomy (RP) between standard dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) and a high spatiotemporal resolution, continuously acquired Golden-angle RAdial Sparse Parallel (...) acquisition employing compressed sensing reconstruction ("GRASP").A search was conducted for prostate MRI examinations performed in patients with PSA ≥0.2 ng/mL after RP in whom follow-up evaluation allowed classification as positive (≥50% PSA reduction after pelvic radiation or positive biopsy) or negative (<50% PSA reduction after pelvic radiation; spontaneous PSA normalization) for LR, yielding 13 patients with standard DCE (11 LR+) and 12 with GRASP (10 LR+). Standard DCE had voxel size 3.0 × 1.9

2017 Abdominal radiology (New York)

289. Prostate cancer bone metastases on staging prostate MRI: prevalence and clinical features associated with their diagnosis Full Text available with Trip Pro

Prostate cancer bone metastases on staging prostate MRI: prevalence and clinical features associated with their diagnosis Bone lesions on prostate MRI often raise concern about metastases. This study aimed to evaluate the prevalence of bone metastases on staging prostate MRI and evaluate associations between their MRI features and clinical/pathologic characteristics.Retrospective, IRB-approved study of 3765 patients undergoing prostate MRI for newly diagnosed PCa between 2000 and 2014 (...) . The reference standard to calculate the prevalence of bone metastases was bone biopsy and/or ≥1-year follow-up after MRI. In a subsample of 228 patients, the MRI characteristics of bone lesions were recorded by two radiologists independently. Associations between MRI and clinical/pathologic findings, including National Comprehensive Cancer Network (NCCN) risk categories, were calculated.57/3765 patients (1.5%, 95% CI 1.2-2.0%) had bone metastases. No patient with NCCN low-risk PCa (Gleason < 7, PSA < 10 ng

2017 Abdominal radiology (New York)

290. Metastatic Prostate Adenocarcinoma to the Brain: Case Reports and Literature Review Full Text available with Trip Pro

Metastatic Prostate Adenocarcinoma to the Brain: Case Reports and Literature Review Cerebral metastasis secondary to prostatic adenocarcinoma is rare and it is usually a late complication in patients with widespread distant metastases. Here, we report two unusual cases of such a rare condition. Our first case presented with a large frontal contrast-enhancing lesion-associated calcification and a large tumor cyst as shown on computed tomography and magnetic resonance imaging. This is the fifth (...) reported case of prostatic metastasis manifesting as a cystic intraparenchymal tumor in the literature. The second case presented with a large soft tissue mass in the scalp and this lesion appeared to invade through the skull and into the middle cranial fossa. He was not known to have prostate cancer before his initial presentation and it was only diagnosed following histology results of the scalp lesion.

2017 Journal of neurological surgery reports

291. In patients with localised prostate cancer, active surveillance is associated with better sexual function, urinary symptoms and bowel symptoms

quality of life among men with localised prostate cancer. JAMA 2017; 317 :1141–50. Context Many patients with prostate cancer are diagnosed with low-risk disease only, for whom the benefit of surgery or radiation on life expectancy may be very limited, while still bringing the risk of side effects. 1 2 Therefore, patients with low-risk prostate cancer are currently offered the option of active surveillance. This strategy delays therapy with curative intent until progression occurs, or it may (...) In patients with localised prostate cancer, active surveillance is associated with better sexual function, urinary symptoms and bowel symptoms In patients with localised prostate cancer, active surveillance is associated with better sexual function, urinary symptoms and bowel symptoms | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we

2017 Evidence-Based Medicine

292. Randomised controlled trial: Similar prostate cancer and all-cause mortality in men with localised prostate cancer undergoing surgery or radiation therapy versus active monitoring at 10?years of follow-up Full Text available with Trip Pro

prostatectomy (RPX), radiation therapy (XRT) and watchful waiting/observation to provide the evidence base for treating men with clinically localised PCA. The Scandinavian Prostate Cancer Group-4 (SPCG-4) trial randomised 695 men diagnosed in the pre-prostate-specific antigen (PSA) era, most had palpable disease, to surgery or observation. 1 After a median follow-up of 13.4 years, surgery reduced PCA deaths by 44% (HR=0.56; 95% CI 0.41 to 0.77; absolute risk reduction=11 percentage points). All-cause (...) mortality was reduced by 12.7 percentage points. Reductions were confined to men <65 years of age. The Prostate Cancer Intervention Versus Observation Trial (PIVOT) randomised 731 men from the early PSA era to RPX or observation. 2 After a 10-year median follow-up, surgery did not reduce disease-specific mortality (HR=0.63; 95% CI 0.36 to 1.09). There was also no significant reduction for all-cause mortality. Absolute differences were <3 percentage points for PCA and all-cause mortality. However

2017 Evidence-Based Medicine

293. Brachytherapy for patients with prostate cancer: American Society of Clinical Oncology/Cancer Care Ontario joint guideline update.

of the guideline. This guideline updates a previous version: Rodrigues G, Yao X, Loblaw A, Brundage M, Chin J, Genitourinary Cancer Disease Site Group. Low-dose rate brachytherapy for patients with low- or intermediate-risk prostate cancer. Toronto (ON): Cancer Care Ontario (CCO); 2012 Oct 31. 55 p. (Evidence-based series; no. 3-10). [165 references] This guideline meets NGC's 2013 (revised) inclusion criteria. UMLS Concepts ICD9CM (185), (60.5) MSH , , , , , , , , MTH , , , , , , , , PDQ , , , , SNOMEDCT_US (...) brachytherapy; no recommendation can be made for or against using 131 Cs or HDR monotherapy. Patients should be encouraged to participate in clinical trials to test novel or targeted approaches to this disease. None provided Prostate cancer Treatment Nuclear Medicine Oncology Radiation Oncology Surgery Urology Physicians To provide oncologists, other health care practitioners, patients, and caregivers with recommendations regarding the use of brachytherapy for patients with prostate cancer that includes

2017 National Guideline Clearinghouse (partial archive)

294. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline.

; Evidence Level: Grade B ) Effective shared decision making in prostate cancer care requires clinicians to inform patients about immediate and long-term morbidity or side effects of proposed treatment or care options. ( Clinical Principle ) Clinicians should inform patients about suitable clinical trials and encourage patients to consider participation in such trials based on eligibility and access. ( Expert Opinion ) Care Options by Cancer Severity/Risk Group Very Low-/Low-Risk Disease Clinicians (...) . ( Expert Opinion ) Intermediate-Risk Disease Clinicians should consider staging unfavorable intermediate-risk localized prostate cancer patients with cross sectional imaging (CT or magnetic resonance imaging [MRI]) and bone scan. ( Expert Opinion ) Clinicians should recommend radical prostatectomy or radiotherapy plus ADT as standard treatment options for patients with intermediate-risk localized prostate cancer. ( Strong Recommendation; Evidence Level: Grade A ) Clinicians should inform patients

2017 National Guideline Clearinghouse (partial archive)

295. Clinically Localized Prostate Cancer Guideline

stratified by cancer severity (or risk group) to facilitate care decisions and second, to guide the specifics of implementing the selected management options, including active surveillance, observation/watchful waiting, prostatectomy, radiotherapy, cryosurgery, high intensity focused ultrasound (HIFU) and focal therapy. Secondary or salvage treatment for localized prostate cancer that persists or recurs after primary definitive intervention, and primary treatment of locally advanced/metastatic disease (...) immediate and long-term morbidity or side effects of proposed treatment or care options. (Clinical Principle) 5. Clinicians should inform patients about suitable clinical trials and encourage patients to consider participation in such trials based on eligibility and access. (Expert Opinion) CARE OPTIONS BY CANCER SEVERITY/RISK GROUP Very Low-/Low-Risk Disease 6. Clinicians should not perform abdomino-pelvic CT or routine bone scans in the staging of asymptomatic very low- or low-risk localized prostate

2017 American Society for Radiation Oncology

296. Brachytherapy for Patients With Prostate Cancer Full Text available with Trip Pro

to this disease. Additional information is available at and . INTRODUCTION Section: The goal of this update is to provide oncologists, other health care practitioners, patients, and caregivers with recommendations regarding the use of brachytherapy for patients with prostate cancer that includes the most recent evidence. Prostate cancer is the most commonly diagnosed cancer in men. In 2016, it is estimated that there will be 180,890 new cases, along with an estimated 26,120 deaths. For this reason (...) , there is great interest in finding optimum treatment strategies to reduce the burden of disease in this patient population. The Cancer Care Ontario systematic review and clinical practice guideline on low–dose rate (LDR) brachytherapy for patients with low- or intermediate-risk prostate cancer were both published in 2013, and since then randomized evidence has been made available that might alter the original recommendations. The goal of this joint update is to consider this new evidence and determine

2017 American Society of Clinical Oncology Guidelines

297. Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline

Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline Prostate Cancer: Clinically Localized Guideline - American Urological Association advertisement Toggle navigation About Us About the AUA Membership AUA Governance Industry Relations Education AUAUniversity Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Prostate Kidney Renovascular Diseases Andrenal Gland Testis Paratesticular Tumors Penis Retroperitoneum Cytology Online (...) and second, to guide the specifics of implementing the selected management options, including active surveillance, observation/watchful waiting, prostatectomy, radiotherapy, cryosurgery, high intensity focused ultrasound (HIFU) and focal therapy. Secondary or salvage treatment for localized prostate cancer that persists or recurs after primary definitive intervention, and primary treatment of locally advanced/metastatic disease, are outside the scope of these guidelines. The content of these guidelines

2017 American Urological Association

298. Post-treatment Follow-up of Prostate Cancer

in radical prostatectomy specimens. J Urol. 2005;174(3):903-907. 91. Zietman AL, Edelstein RA, Coen JJ, Babayan RK, Krane RJ. Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology. 1994;43(6):828-833. 92. Martino P, Scattoni V, Galosi AB, et al. Role of imaging and biopsy to assess local recurrence after definitive treatment for prostate carcinoma (surgery, radiotherapy, cryotherapy, HIFU). World J Urol (...) Post-treatment Follow-up of Prostate Cancer Revised 2017 ACR Appropriateness Criteria ® 1 Post-treatment Follow-up of Prostate Cancer American College of Radiology ACR Appropriateness Criteria ® Post-treatment Follow-up of Prostate Cancer Variant 1: Prostate cancer follow-up. Status post radical prostatectomy. Clinical concern for residual or recurrent disease. Procedure Appropriateness Category Relative Radiation Level C-11 choline PET/CT skull base to mid-thigh Usually Appropriate ??? MRI

2017 American College of Radiology

299. 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0

-prostatecancerssuchascoloncan- cer,esophagealcancer,thyroidcancer,lungcancer,renal cell carcinoma, and brain tumours, as well as in benign tissue [1, 45–49].Sofar,avarietyofmainlycasereportsexistsshowing increased PSMA uptake in non-prostate cancer-related le- sions. An important pitfall is relevant PSMA ligand uptake in coeliac ganglia of the autonomic nervous system which is pronetobemisinterpretedasretroperitoneallymphnodeme- tastases [50]. Moreover, uptake in Paget’s bone disease, in stellate (...) . Prostate-specific membrane antigen expression in normal and ma- lignanthumantissues.ClinCancerRes.1997;3:81–5. 2. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998;82:2256–61. 3. Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant

2017 Society of Nuclear Medicine and Molecular Imaging

300. In localised prostate cancer, radical prostatectomy was associated with more sexual dysfunction and urinary incontinence than radiation or active surveillance

In localised prostate cancer, radical prostatectomy was associated with more sexual dysfunction and urinary incontinence than radiation or active surveillance In localised prostate cancer, radical prostatectomy was associated with more sexual dysfunction and urinary incontinence than radiation or active surveillance | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any (...) time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here In localised prostate cancer, radical prostatectomy was associated

2017 Evidence-Based Medicine